公开(公告)号：US20230287069A1

公开(公告)日：2023-09-14

申请号：US17819470

申请日：2022-08-12

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  A61K35/17 ,  G01N33/574 ,  C07K16/30 ,  C12N5/0783 ,  A61K39/00 ,  C07K14/725 ,  A61P35/00 ,  C12N15/10 ,  C07K7/06 ,  C07K14/54 ,  C07K14/74 ,  C12N15/115 ,  C07K16/28

CPC classification number: C07K14/4748 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/001102 ,  A61P35/00 ,  C07K7/06 ,  C07K14/5434 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/30 ,  C07K16/2818 ,  C12N5/0638 ,  C12N15/115 ,  C12N15/1062 ,  G01N33/57492 ,  A61K38/00 ,  A61K2039/572 ,  C07K2319/00 ,  C12N2501/50

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230285462A1

公开(公告)日：2023-09-14

申请号：US18185653

申请日：2023-03-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/2818 ,  C07K7/06 ,  C07K14/5434 ,  A61P35/02 ,  A61K39/001102 ,  A61K45/06 ,  C12N5/0636 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  C07K16/244 ,  A61K39/39558 ,  C07K16/2821 ,  A61K38/08 ,  C07K14/4748 ,  A61K2039/5156 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230279066A1

公开(公告)日：2023-09-07

申请号：US18297076

申请日：2023-04-07

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/10 ,  C12N15/115 ,  G01N33/574 ,  A61K35/17 ,  C07K7/06 ,  C07K14/54

CPC classification number: C07K14/4748 ,  A61P35/00 ,  A61K39/001102 ,  A61K39/0011 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2818 ,  C07K16/30 ,  C12N5/0638 ,  C12N15/1062 ,  C12N15/115 ,  G01N33/57492 ,  A61K35/17 ,  C07K7/06 ,  C07K14/5434 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2319/00 ,  C12N2501/50 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230265158A1

公开(公告)日：2023-08-24

申请号：US18054566

申请日：2022-11-11

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  C12N9/64 ,  G01N33/566 ,  C12N5/0783 ,  C07K14/47 ,  G01N33/569 ,  C12Q1/6886 ,  A61K45/06 ,  A61K39/00 ,  A01N37/46 ,  A61K38/17 ,  C07K16/28 ,  A61K38/06 ,  C07K14/00 ,  C07K16/30 ,  A61K38/08 ,  C07K16/18 ,  G01N33/50 ,  C07K7/02 ,  C07K7/06 ,  C07K14/725 ,  A61K38/00

CPC classification number: C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/30 ,  C07K16/2833 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/566 ,  G01N33/5088 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  A61K2039/5158 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/47 ,  G01N2333/7051 ,  G01N2333/70503 ,  G01N2333/70539 ,  G01N2500/10

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US20230242604A1

公开(公告)日：2023-08-03

申请号：US18170154

申请日：2023-02-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Heiko SCHUSTER ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12Q1/6886

CPC classification number: C07K14/4748 ,  A61K35/17 ,  A61K39/0011 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/18 ,  C12N5/0636 ,  C12Q1/6886 ,  G16B25/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230241110A1

公开(公告)日：2023-08-03

申请号：US18164418

申请日：2023-02-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/2818 ,  C07K7/06 ,  C07K14/5434 ,  A61P35/02 ,  A61K39/001102 ,  A61K45/06 ,  C12N5/0636 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  C07K16/244 ,  A61K39/39558 ,  C07K16/2821 ,  A61K38/08 ,  C07K14/4748 ,  A61K2039/5156 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230235016A1

公开(公告)日：2023-07-27

申请号：US18052824

申请日：2022-11-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  A61K38/06 ,  C12N9/64 ,  C12N5/0783 ,  C07K16/30 ,  C07K14/47 ,  A61K39/00 ,  C07K16/28 ,  A61K45/06 ,  C07K14/00 ,  C07K7/06 ,  C07K7/02 ,  G01N33/50 ,  G01N33/566 ,  C07K16/18 ,  A61K38/08 ,  C07K14/725 ,  G01N33/569 ,  A61K38/17 ,  C12Q1/6886 ,  A01N37/46

CPC classification number: C07K14/70539 ,  A61K38/06 ,  C12N9/6491 ,  C12N5/0636 ,  C07K16/30 ,  C07K14/4748 ,  A61K39/0011 ,  C07K16/2833 ,  A61K45/06 ,  C07K14/001 ,  C07K7/06 ,  C07K7/02 ,  G01N33/505 ,  G01N33/566 ,  G01N33/5088 ,  A61K39/0005 ,  C07K16/18 ,  C07K14/47 ,  C12N5/0638 ,  A61K38/08 ,  C07K14/7051 ,  G01N33/56972 ,  C07K14/4702 ,  A61K38/1774 ,  C12Q1/6886 ,  G01N33/56977 ,  A01N37/46 ,  C07K2317/34 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2333/7051 ,  A61K2039/54 ,  G01N2333/70539 ,  C07K2317/31 ,  C07K2317/24 ,  G01N2333/70503 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2502/11 ,  A61K2039/572 ,  G01N2333/47 ,  C12N2501/998 ,  C12Y304/24 ,  A61K2039/57 ,  A61K2039/585 ,  A61K38/00

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US20230233612A1

公开(公告)日：2023-07-27

申请号：US18176678

申请日：2023-03-01

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/2818 ,  C07K7/06 ,  C07K14/5434 ,  A61P35/02 ,  A61K39/001102 ,  A61K45/06 ,  C12N5/0636 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  C07K16/244 ,  A61K39/39558 ,  C07K16/2821 ,  A61K38/08 ,  C07K14/4748 ,  A61K2039/5156 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230226161A1

公开(公告)日：2023-07-20

申请号：US18158606

申请日：2023-01-24

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  A61P35/00 ,  C12Q1/6886 ,  C12N15/115 ,  C07K16/28 ,  C07K14/74 ,  C07K16/30 ,  G01N33/574 ,  C07K7/08 ,  C07K14/725 ,  C12N5/0783 ,  C07K7/06 ,  C07K14/47

CPC classification number: A61K39/0011 ,  A61P35/00 ,  C12Q1/6886 ,  C12N15/115 ,  C07K16/2833 ,  C07K14/70539 ,  C07K16/3076 ,  G01N33/57492 ,  C07K7/08 ,  C07K14/7051 ,  C12N5/0636 ,  C07K7/06 ,  C07K14/4748 ,  C12Q2600/106 ,  G01N2333/70539 ,  A61K39/00 ,  A61K2039/5158 ,  C12N2310/16 ,  C12Q2600/156 ,  C12N2501/50 ,  C07K2319/40

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230212244A1

公开(公告)日：2023-07-06

申请号：US18063418

申请日：2022-12-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Oliver SCHOOR ,  Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/113 ,  C07K14/725 ,  C07K16/30

CPC classification number: C07K14/4748 ,  A61K39/0011 ,  A61K39/001154 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/3046 ,  C07K16/3076 ,  C12N5/0636 ,  C12N15/1138 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K2317/34 ,  C12N2310/16 ,  C12N2501/50

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.